These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11772238)

  • 41. Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.
    Landriscina M; Bagalà C; Piscazzi A; Schinzari G; Quirino M; Fabiano A; Bianchetti S; Cassano A; Sica G; Barone C
    Prostate; 2009 May; 69(7):744-54. PubMed ID: 19152342
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interaction of IGF signaling and the androgen receptor in prostate cancer progression.
    Wu JD; Haugk K; Woodke L; Nelson P; Coleman I; Plymate SR
    J Cell Biochem; 2006 Oct; 99(2):392-401. PubMed ID: 16639715
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bone-targeting agents in prostate cancer.
    Suzman DL; Boikos SA; Carducci MA
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):619-28. PubMed ID: 24398856
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
    Zhang M; Latham DE; Delaney MA; Chakravarti A
    Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Androgen synthesis in prostate cancer: do all roads lead to Rome?
    Stuchbery R; McCoy PJ; Hovens CM; Corcoran NM
    Nat Rev Urol; 2017 Jan; 14(1):49-58. PubMed ID: 27824348
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions.
    Isaacsson Velho P; Carducci MA
    Expert Opin Investig Drugs; 2018 Oct; 27(10):811-822. PubMed ID: 30118330
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Androgen Receptor Antagonists Suppress Immunotherapy in Prostate Cancer.
    Cancer Discov; 2016 Jun; 6(6):569. PubMed ID: 27102077
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?
    Aggarwal RR; Ryan CJ; Chan JM
    Urol Oncol; 2013 Jul; 31(5):522-30. PubMed ID: 21658978
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug insight: role of the androgen receptor in the development and progression of prostate cancer.
    Taplin ME
    Nat Clin Pract Oncol; 2007 Apr; 4(4):236-44. PubMed ID: 17392714
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Androgens and prostate cancer: biology, pathology and hormonal therapy.
    Galbraith SM; Duchesne GM
    Eur J Cancer; 1997 Apr; 33(4):545-54. PubMed ID: 9274433
    [No Abstract]   [Full Text] [Related]  

  • 51. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer.
    Chatterjee B
    Mol Cell Biochem; 2003 Nov; 253(1-2):89-101. PubMed ID: 14619959
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Molecular mechanisms involved in hormone resistance of prostate cancer].
    Cabrespine A; Guy L; Chollet P; Debiton E; Bay JO
    Bull Cancer; 2004 Oct; 91(10):747-57. PubMed ID: 15556875
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Androgen receptor inhibition suppresses anti-tumor neutrophil response against bone metastatic prostate cancer via regulation of TβRI expression.
    Alsamraae M; Costanzo-Garvey D; Teply BA; Boyle S; Sommerville G; Herbert ZT; Morrissey C; Dafferner AJ; Abdalla MY; Fallet RW; Kielian T; Jensen-Smith H; deOliveira EI; Chen K; Bettencourt IA; Wang JM; McVicar DW; Keeley T; Yu F; Cook LM
    Cancer Lett; 2023 Nov; 579():216468. PubMed ID: 37940068
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The basic biochemistry and molecular events of hormone therapy.
    Mostaghel EA; Montgomery RB; Lin DW
    Curr Urol Rep; 2007 May; 8(3):224-32. PubMed ID: 17459272
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice.
    Chisamore MJ; Gentile MA; Dillon GM; Baran M; Gambone C; Riley S; Schmidt A; Flores O; Wilkinson H; Alves SE
    J Steroid Biochem Mol Biol; 2016 Oct; 163():88-97. PubMed ID: 27106747
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
    Alberti C
    G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
    Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
    BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Androgen receptor signaling in prostate cancer.
    Culig Z; Santer FR
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):413-27. PubMed ID: 24384911
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular regulation of androgen action in prostate cancer.
    Dehm SM; Tindall DJ
    J Cell Biochem; 2006 Oct; 99(2):333-44. PubMed ID: 16518832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.